B.Riley initiates coverage on Microbot Medical stock with Buy rating
#Microbot Medical #B. Riley Securities #Liberty Robotic System #Surgical Robotics #Buy Rating #Medical Devices #Nasdaq
📌 Key Takeaways
- B. Riley Securities initiated coverage of Microbot Medical with a 'Buy' rating.
- The analyst set a 12-month price target of $7.00 per share, indicating high growth expectations.
- The positive outlook is driven by the potential of the Liberty Endovascular Robotic System.
- Microbot's technology focuses on disposable, portable robotics to improve safety and accessibility in surgery.
📖 Full Retelling
Investment firm B. Riley Securities initiated formal analyst coverage on Microbot Medical Inc. on May 22, 2024, issuing a 'Buy' rating and a $7.00 price target for the company's stock trading on the Nasdaq. The move comes as Wall Street analysts increasingly focus on the promising trajectory of Microbot's surgical robotics technology, specifically its flagship Liberty Endovascular Robotic System. B. Riley’s positive assessment is rooted in the device's potential to revolutionize minimally invasive procedures and the company's clear path toward clinical validation and commercialization in the United States and international markets.
Microbot Medical, a clinical-stage medical device company, is currently navigating the regulatory landscape with its Liberty system, which aims to be the world's first fully disposable robotic system for endovascular procedures. By eliminating the need for large, capital-intensive equipment and specialized infrastructure, the Liberty system is designed to reduce radiation exposure for physicians and improve the precision of catheter-based interventions. The $7.00 price target set by B. Riley suggests a significant upside potential from the stock's current trading levels, reflecting confidence in the company's upcoming IDE (Investigational Device Exemption) clinical trial results.
The initiation of coverage by a prominent firm like B. Riley serves as a critical milestone for Microbot, as it often leads to increased visibility among institutional investors and enhances market liquidity. Industry experts suggest that the surgical robotics sector is ripe for disruption, and Microbot's focus on portability and disposability addresses key pain points in modern operating rooms. As the company prepares for its multi-center human clinical trials, the financial community will be closely monitoring its ability to meet enrollment milestones and demonstrate the safety and efficacy of its robotic platform.
🏷️ Themes
Finance, Healthcare Technology, Stock Market
📚 Related People & Topics
Medical device
Device to be used for medical purposes
A medical device is any device intended to be used for medical purposes. Significant potential for hazards are inherent when using a device for medical purposes and thus medical devices must be proved safe and effective with reasonable assurance before regulating governments allow marketing of the d...
🔗 Entity Intersection Graph
Connections for Medical device:
- 🌐 Transcatheter aortic valve replacement (1 shared articles)
- 🏢 Stifel (1 shared articles)
- 🏢 Edwards Lifesciences (1 shared articles)
- 🏢 BlackRock (1 shared articles)
- 🌐 SEC filing (1 shared articles)
- 🌐 Asset management (1 shared articles)
📄 Original Source Content
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry As Claude disrupts stock market, Anthropic researcher warns ’world is in peril’ Gold, silver prices rise amid U.S.-Iran tensions, blowout January payrolls data Dow halts three-day win streak as blowout jobs data curbs rate cut bets Citi pushes back Fed rate cuts to May after blowout January jobs report (South Africa Philippines Nigeria) B.Riley initiates coverage on Microbot Medical stock with Buy rating Analyst Ratings Published 02/10/2026, 02:03 AM B.Riley initiates coverage on Microbot Medical stock with Buy rating 0 MBOT -2.44% Investing.com - B.Riley has initiated coverage on Microbot Medical (NASDAQ:MBOT) with a Buy rating and a $5.00 price target, representing a 172% upside from the current price of $1.84. According to InvestingPro data, analyst consensus remains bullish with a high target of $12. The firm’s coverage begins shortly after Microbot Medical received FDA 510 clearance for its LIBERTY Endovascular Robotic System in September 2025 and commenced its U.S. limited market release in November 2025. The $123.57M market cap company is scheduled to report its next earnings on February 25, 2026. Emory University Hospital became the first institution to adopt the LIBERTY system, which is the first and only single-use, remotely operated robotic platform cleared by the FDA for peripheral vascular procedures. B.Riley notes that LIBERTY addresses a market opportunity in the peripheral vascular space, with more than 2.3 million procedures performed annually in the U.S. and no current robotic competition. The firm highlights that unlike capital equipment robotics platforms requiring high upfront investment, LIBERTY’s fully disposable model flows through operating budgets for hospitals and surgery centers, potentially enabling faster commercial adoption. InvestingPro data shows Microbot holds more cash than debt on its balance sheet with a strong current ratio of 27.53, supporting its commercialization effor...